| Joseph M Ojile, MD | |
|
11200 Tesson Ferry Rd, Suite 100, Saint Louis, MO 63123-6922 | |
| (314) 849-1500 | |
| (314) 849-8789 |
| Full Name | Joseph M Ojile |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 40 Years |
| Location | 11200 Tesson Ferry Rd, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003895236 | NPI | - | NPPES |
| 202899316 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | R3F72 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital St Louis | Saint louis, MO | Hospital |
| Mercy Hospital South | Saint louis, MO | Hospital |
| Mercy Hospital Jefferson | Festus, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Caduceus Corporation | 3678527553 | 2 |
News Archive
An alternative amplification technique to detect SARS-CoV-2 RNA could offer a way to rapidly test large numbers of people for COVID-19, although the technique is not as sensitive as quantitative RT-PCR, the current standard method for COVID-19 testing.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
Vertex Pharmaceuticals Incorporated today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate principal amount of notes. The exercise of the option brings the total aggregate principal amount of notes sold in the offering to $400 million
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.
› Verified 1 days ago
| Entity Name | Caduceus Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295785848 PECOS PAC ID: 3678527553 Enrollment ID: O20050303000969 |
News Archive
An alternative amplification technique to detect SARS-CoV-2 RNA could offer a way to rapidly test large numbers of people for COVID-19, although the technique is not as sensitive as quantitative RT-PCR, the current standard method for COVID-19 testing.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
Vertex Pharmaceuticals Incorporated today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate principal amount of notes. The exercise of the option brings the total aggregate principal amount of notes sold in the offering to $400 million
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph M Ojile, MD 11222 Tesson Ferry Rd, Suite 100, Saint Louis, MO 63123-6963 Ph: (314) 849-1500 | Joseph M Ojile, MD 11200 Tesson Ferry Rd, Suite 100, Saint Louis, MO 63123-6922 Ph: (314) 849-1500 |
News Archive
An alternative amplification technique to detect SARS-CoV-2 RNA could offer a way to rapidly test large numbers of people for COVID-19, although the technique is not as sensitive as quantitative RT-PCR, the current standard method for COVID-19 testing.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
Vertex Pharmaceuticals Incorporated today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate principal amount of notes. The exercise of the option brings the total aggregate principal amount of notes sold in the offering to $400 million
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.
› Verified 1 days ago
Dr. Isik Turker, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 4921 Parkview Pl, Div Im Cardiology, Ste 8b, Saint Louis, MO 63110 Phone: 314-362-1291 Fax: 314-362-4278 | |
Conor Mccartney, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 915 N Grand Blvd, Saint Louis, MO 63106 Phone: 314-652-4100 | |
Dr. Faris Adam Bakeer, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Barnes Jewish Hospital Plz, Div Im Hospitalist, Saint Louis, MO 63110 Phone: 314-362-1700 Fax: 314-362-9878 | |
Rehan Rais, M.D. M.B.,B.S. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 660 S Euclid Ave, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Nathan Farkas, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Barnes Jew Hosp Plz, Saint Louis, MO 63110 Phone: 314-362-1930 | |
Dr. Nicole Foley, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-362-5000 | |
Soumojit Ghosh, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3660 Vista Ave, Saint Louis, MO 63110 Phone: 314-977-6100 Fax: 314-977-6164 |